Bel­gian up­start Rewind taps Ian Reynolds as CEO; Robert Fos­ter takes the reins at Con­traVir

→ With $17 mil­lion of Se­ries A mon­ey in tow, Bel­gian biotech Rewind Ther­a­peu­tics has found a new leader in Ian Reynolds, a “tal­ent­ed drug-hunter” in neu­ro­science who trad­ed a tenured pro­fes­sor­ship for dis­cov­ery roles in bio­phar­ma, most re­cent­ly VP and head of dis­cov­ery re­search at Te­va’s US unit. As CEO, Reynolds will lead Rewind to ad­vance treat­ments for myelin-re­lat­ed dis­eases to the clin­ic in close col­lab­o­ra­tion with their founders at KU Leu­ven’s Cen­tre for Drug De­sign and Dis­cov­ery and Axxam. Boehringer In­gel­heim and Mer­ck’s ven­ture arms are back­ing the com­pa­ny along­side Flem­ish in­vest­ment com­pa­ny PMV.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER